Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Spruce Biosciences Inc
SPRBCurrent price
0.33 USD
-0.017 USD (-4.93%)
Last closed
0.34 USD
Company
www.sprucebiosciences.com
ISIN
US85209E1091
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
16 054 321 USD
Yield for 12 month
-54.24 %
1Y
3Y
5Y
10Y
15Y
SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.83 USDP/E ratio
–Dividend Yield
–Current Year
+10 089 000 USD
Last Year
+1 964 000 USD
Current Quarter
+602 000 USD
Last Quarter
+1 610 000 USD
Current Year
-39 343 000 USD
Last Year
-429 000 USD
Current Quarter
+602 000 USD
Last Quarter
-6 480 000 USD
Key Figures SPRB
1 year
3 years
5 years
10 years
EBITDA
-43 188 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-30.35 %
PEG Ratio
–
Return On Equity TTM
-57.55 %
Wall Street Target Price
1.83 USD
Revenue TTM
7 101 000 USD
Book Value
1.25 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-80.40 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.95 USD
Diluted Eps TTM
-0.95 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SPRB
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History SPRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation SPRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
15.32
Price Sales TTM
2.26
Enterprise Value EBITDA
-0.23
Price Book MRQ
0.31
Financials SPRB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SPRB
For 52 weeks
0.37 USD
5.95 USD
50 Day MA
0.51 USD
Shares Short Prior Month
71 034
200 Day MA
0.79 USD
Short Ratio
0.10
Shares Short
30 676
Short Percent
0.080 %
BeatStart